PDCD1 and glioblastoma: Since anti-PD-1 treatment can act through TAMs, the major immune cell population in GBM tissue, the prospect of this treatment regimen in GBM patients is still present [134] in spite of the failure of the phase III CheckMate 143 trial [137].